NCT06878118

The A.R.R.E.S.T.® Contact Lens Study

Recruiting now NA Last updated 3 October 2025

What this trial tests

NA trial testing Single-vision contact lens in Myopia in 80 participants. Currently enrolling.

Timeline

6 July 2025

Primary endpoint
1 May 2026

1 November 2026

Quick facts

Lead sponsor	nthalmic Pty Ltd
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	80
Start date	6 July 2025
Primary completion	1 May 2026
Estimated completion	1 November 2026
Sites	2 locations across China, Malaysia

Drugs / interventions tested

• Single-vision contact lens
• A.R.R.E.S.T.® contact lens

Conditions studied

• Myopia — all drugs for Myopia →
• Myopia Progression — all drugs for Myopia Progression →

Sponsor

nthalmic Pty Ltd

Who can join

Adults 7 to 15, any sex, with Myopia or Myopia Progression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to learn if contact lenses using Active Reconfiguration in Retinal Encoding of Spatio-Temporal (A.R.R.E.S.T.®) signal technology works to slow down the rate of myopia progression compared to single vision contact lenses in myopic children. The main questions it aims to answer are:

Do contact lenses using A.R.R.E.S.T.® technology slow down the rate of axial length growth? Do contact lenses using A.R.R.E.S.T.® technology slow down the rate of increase in myopic refractive error?

Researchers will compare contact lenses using A.R.R.E.S.T.® technology to a single vision contact lens.

Participants will:

Be randomly allocated to wear either contact lenses using A.R.R.E.S.T.® technology or single vision contact lenses.

Visit the clinic on seven occasions over a 12 month period.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.